TY - JOUR
T1 - Allogeneic Hematopoietic Cell Transplantation for Myeloma
T2 - When and in Whom Does It Work
AU - Bashir, Qaiser
AU - Qazilbash, Muzaffar H.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - The growing list of available therapies for patients with multiple myeloma has resulted in tremendously high response rates and prolonged survival. However, the cure remains elusive. A continued effort at developing strategies to utilize all available treatment modalities in the most effective manner is needed. Allogeneic hematopoietic cell transplantation (allo-HCT) is a robust platform, associated with high response rates, and provides a unique foundation on which immune therapies and novel agents can be employed to improve clinical outcomes. Patients with high-risk myeloma and those relapsing after novel agent-based therapies or early after an autologous HCT should be considered for allo-HCT, ideally in a clinical trial setting. Results from several ongoing studies are expected to provide important information that will help determine the place of allo-HCT in the myeloma treatment algorithm.
AB - The growing list of available therapies for patients with multiple myeloma has resulted in tremendously high response rates and prolonged survival. However, the cure remains elusive. A continued effort at developing strategies to utilize all available treatment modalities in the most effective manner is needed. Allogeneic hematopoietic cell transplantation (allo-HCT) is a robust platform, associated with high response rates, and provides a unique foundation on which immune therapies and novel agents can be employed to improve clinical outcomes. Patients with high-risk myeloma and those relapsing after novel agent-based therapies or early after an autologous HCT should be considered for allo-HCT, ideally in a clinical trial setting. Results from several ongoing studies are expected to provide important information that will help determine the place of allo-HCT in the myeloma treatment algorithm.
KW - Allo-HCT
KW - Allogeneic hematopoietic cell transplantation
KW - Autologous HCT
KW - Multiple myeloma
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=85028266316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028266316&partnerID=8YFLogxK
U2 - 10.1007/s11899-017-0374-1
DO - 10.1007/s11899-017-0374-1
M3 - Review article
C2 - 28285435
AN - SCOPUS:85028266316
SN - 1558-8211
VL - 12
SP - 126
EP - 135
JO - Current hematologic malignancy reports
JF - Current hematologic malignancy reports
IS - 2
ER -